Current drug development efforts have been focused on creating IL-2 variants that selectively bind to IL-2Rβ (non-a) instead of IL-2Rα (CD25) to avoid toxicity issues. MustBio is developing a drug with a non-a IL-2 variant that is also designed to have a lower binding affinity of IL-2 to the IL-2Rγ, with the aim of improving the binding of PD-1 at the tumor microenvironment. This improvement is expected to reduce side effects in the peripheral blood, setting it apart from its competitors.

http://m.biospectator.com/view/news_view.php?varAtcId=21720